COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00031642
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : December 17, 2013
Information provided by (Responsible Party):
Julie M Vose, MD, University of Nebraska

Brief Summary:

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Radiolabeled monoclonal antibodies can locate and deliver radioactive cancer-killing substances.

PURPOSE: Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibodies with rituximab in treating patients who have non-Hodgkin's lymphoma that has not responded to high-dose chemotherapy and autologous stem cell transplantation.

Condition or disease Intervention/treatment Phase
Lymphoma Biological: rituximab Radiation: yttrium Y 90 ibritumomab tiuxetan Phase 1 Phase 2

Detailed Description:


  • Determine the maximum tolerated dose of yttrium Y 90-labeled ibritumomab tiuxetan when administered with rituximab in patients with B-cell non-Hodgkin's lymphoma who have relapsed after high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
  • Determine the safety and efficacy of this regimen in these patients.

OUTLINE: This is a dose-escalation study of yttrium Y 90-labeled ibritumomab tiuxetan (IDEC-Y2B8).

  • Phase I: Patients receive rituximab IV over 4-6 hours followed by indium In 111-labeled ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0. Patients receive rituximab IV again on day 7 followed by IDEC-Y2B8 IV over 10 minutes.

Cohorts of 3-6 patients receive escalating doses of IDEC-Y2B8 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 3 of 6 patients experience dose-limiting toxicity.

  • Phase II: Once the MTD is determined, 58 additional patients are treated at that dose level as in phase I.

Patients are followed at 6 weeks, every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 78 patients (20 for phase I and 58 for phase II) will be accrued for this study within 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of IDEC-Y2B8 (Zevalin) for Post Transplant Relapses of B-Cell Non-Hodgkin's Lymphoma
Study Start Date : January 2002
Actual Primary Completion Date : November 2005
Actual Study Completion Date : March 2008

Primary Outcome Measures :
  1. Maximum tolerated dose
  2. Safety and efficacy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of relapsed B-cell non-Hodgkin's lymphoma (NHL) after high-dose chemotherapy and autologous stem cell transplantation
  • Less than 25% bone marrow involvement with NHL as evidenced by unilateral or bilateral biopsy within the past 6 weeks

    • Bone marrow biopsy should demonstrate 15-20% of cellular space occupied by normal hematopoiesis
  • CD20 antigen expression in tumor tissue within the past year as evidenced by 1 of the following:

    • Immunoperoxidase stains of tissue showing positive reactivity with L26 antibody
    • Flow cytometry studies
  • Measurable disease

    • More than 2 cm bidimensionally
  • No active CNS lymphoma
  • No HIV- or AIDS-related lymphoma



  • 19 and over

Performance status:

  • WHO 0-2

Life expectancy:

  • At least 3 months


  • Absolute neutrophil count greater than 1,500/mm^3
  • Platelet count greater than 150,000/mm^3
  • No transfusion dependency


  • Bilirubin less than 2.0 mg/dL
  • SGOT or SGPT no greater than 2.5 times upper limit of normal (unless due to lymphomatous infiltration of the liver)


  • Creatinine less than 2.0 mg/dL
  • No active obstructive hydronephrosis


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 6 months after study therapy
  • HIV negative
  • No active infection requiring oral or IV antibiotics
  • No human antimurine antibody positivity
  • No other major medical problems


Biologic therapy:

  • See Disease Characteristics
  • At least 4 weeks since prior growth factors
  • At least 4 weeks since prior biologic therapy
  • No dependency on hematopoietic growth factors (e.g., epoetin alfa, interleukin-11, filgrastim [G-CSF], or sargramostim [GM-CSF])
  • No prior radioimmunotherapy
  • No other concurrent biologic therapy of any kind


  • See Disease Characteristics
  • At least 4 weeks since any prior cytotoxic chemotherapy (6 weeks for nitrosoureas)
  • No prior fludarabine
  • No concurrent chemotherapy

Endocrine therapy:

  • No concurrent steroids except as maintenance for non-cancerous disease


  • See Biologic therapy
  • At least 4 weeks since prior radiotherapy
  • No prior pelvic radiotherapy
  • No prior radiotherapy to more than 25% of estimated bone marrow reserve
  • No concurrent external beam radiotherapy


  • Not specified


  • Recovered from all prior therapy
  • At least 4 weeks since prior immunosuppressants
  • No other concurrent investigational drugs
  • No other concurrent anti-cancer therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00031642

Layout table for location information
United States, Nebraska
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198-7680
Sponsors and Collaborators
University of Nebraska
Layout table for investigator information
Study Chair: Julie M. Vose, MD University of Nebraska
Layout table for additonal information
Responsible Party: Julie M Vose, MD, Professor, University of Nebraska Identifier: NCT00031642    
Other Study ID Numbers: 535-00
CDR0000069211 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: December 17, 2013
Last Verified: December 2013
Keywords provided by Julie M Vose, MD, University of Nebraska:
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult diffuse large cell lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult Burkitt lymphoma
recurrent mantle cell lymphoma
recurrent marginal zone lymphoma
recurrent small lymphocytic lymphoma
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
nodal marginal zone B-cell lymphoma
splenic marginal zone lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents